Abstract
Introduction: Secukinumab (SEC), a fully human monoclonal antibody that selectively neutralizes interleukin-17A, showed sustained effectiveness and safety in psoriatic diseases (1-5). This abstract presents effectiveness and quality of life improvement data for patients treated with secukinumab across weight categories up to 36 months in the PURE registry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
